While amyloidosis may seem like a rare disease, the statistics tell a more complex story: its many forms touch far more lives than you might think, impacting everyone from patients on long-term dialysis to otherwise healthy elderly individuals.
Key Takeaways
- The annual incidence of AL amyloidosis in the United States is approximately 12.8 cases per million person-years
- In Europe, the incidence of systemic AL amyloidosis is estimated at 8-12 cases per million population per year
- ATTR amyloidosis prevalence in individuals over 60 years old is about 1 in 300 in autopsy studies from Western populations
- AL amyloidosis is classified into immunoglobulin light chain (AL), accounting for ~70% of systemic cases
- Transthyretin (ATTR) amyloidosis is divided into wild-type (ATTRwt) and variant (ATTRv) subtypes, with ATTRwt being age-related
- AA amyloidosis is secondary to chronic inflammation, derived from serum amyloid A protein
- Most common symptom in AL amyloidosis is fatigue, present in 90% of patients at diagnosis
- Peripheral neuropathy affects 20-30% of AL amyloidosis patients, often painful small-fiber type
- Cardiac involvement in amyloidosis presents with heart failure symptoms in 50-60% of systemic cases
- Serum free light chain ratio abnormal in 95% of AL amyloidosis at diagnosis
- Congo red staining with apple-green birefringence under polarized light confirmatory for amyloid, sensitivity 100%
- Technetium-99m pyrophosphate (Tc-PYP) scan specificity >90% for ATTR cardiac amyloidosis
- Chemotherapy with bortezomib-based regimens achieves hematologic response in 60-70% newly diagnosed AL
- Daratumumab added to CyBorD increases CR rate to 53% vs 18% in AL amyloidosis
- Tafamidis stabilizes TTR, reduces mortality by 30% in ATTR cardiomyopathy (ATTR-ACT trial)
Amyloidosis, including its common types AL and ATTR, varies widely in incidence, diagnosis age, and survival.
Diagnosis
1Serum free light chain ratio abnormal in 95% of AL amyloidosis at diagnosis
Verified2Congo red staining with apple-green birefringence under polarized light confirmatory for amyloid, sensitivity 100%
Verified3Technetium-99m pyrophosphate (Tc-PYP) scan specificity >90% for ATTR cardiac amyloidosis
Verified4Bone marrow biopsy shows plasma cells >10% in 60-70% of AL amyloidosis
Directional5Mass spectrometry on laser microdissected tissue identifies amyloid protein type in 95% cases
Single source6Echocardiography shows increased left ventricular wall thickness >12mm in 90% cardiac amyloid
Verified7Serum cardiac troponin T elevated in 75% of AL cardiac amyloidosis
Verified8NT-proBNP >1800 pg/mL highly suggestive of cardiac amyloid in low-flow low-gradient AS
Verified9Genetic testing for TTR mutations positive in 100% hereditary ATTRv
Directional10Urine/serum immunofixation detects M-protein in 90% AL amyloidosis
Single source11Cardiac MRI late gadolinium enhancement in subendocardium specificity 90% for amyloid
Verified12Kidney biopsy immunofluorescence shows light chain restriction in AL renal amyloid
Verified13Scintigraphy with 99mTc-DPD similar to PYP, Grade 2-3 uptake diagnostic for ATTR
Verified14Flow cytometry on bone marrow detects clonal plasma cells in 80% AL
Directional15Abdominal fat pad aspirate sensitivity 70-80% for systemic amyloid detection
Single source16Strain echocardiography global longitudinal strain <-15% with apical sparing pattern in 85%
Verified17SAA protein levels >10mg/L indicate risk for AA amyloidosis in chronic inflammation
Verified18Beta-2 microglobulin >28mg/L in dialysis patients suggests Aβ2M amyloidosis
Verified19PET-CT with amyloid tracers like 18F-florbetapir emerging for non-invasive typing
Directional20Mayo AL staging: troponin, NT-proBNP, dFLC stratifies risk with median survival 94 vs 12 months
Single source21Rectal biopsy sensitivity 80% for systemic amyloidosis diagnosis
Verified22Electrophysiology shows small-fiber neuropathy in skin biopsy for early ATTRv
Verified23Liver biopsy for hepatomegaly shows amyloid in sinusoids
Verified24Urine protein electrophoresis shows Bence Jones proteins in 70% AL
Directional25ECG low voltage despite hypertrophy in 60% cardiac amyloidosis
Single source26Complete hematologic response (CR) defined as dFLC <10mg/L and normal ratio in AL treatment
VerifiedDiagnosis Interpretation
This collection of data makes amyloidosis diagnostics feel like assembling a sinister jigsaw puzzle, where each piece, from the eerie green glow of a Congo red stain to the cardiac MRI's specific pattern of scarring, fits together to reveal a precise and often ominous picture of protein infiltration.
Epidemiology
1The annual incidence of AL amyloidosis in the United States is approximately 12.8 cases per million person-years
Verified2In Europe, the incidence of systemic AL amyloidosis is estimated at 8-12 cases per million population per year
Verified3ATTR amyloidosis prevalence in individuals over 60 years old is about 1 in 300 in autopsy studies from Western populations
Verified4AA amyloidosis accounts for 2-5% of all renal biopsies in developing countries due to chronic infections
Directional5The median age at diagnosis for light chain (AL) amyloidosis is 63 years, with 60% of patients being male
Single source6Hereditary amyloidosis due to TTR mutations has a prevalence of 1 in 100,000 worldwide but higher in specific endemic areas like Portugal
Verified7Dialysis-related amyloidosis (Aβ2M) affects up to 20% of patients on long-term hemodialysis after 5 years
Verified8Localized cutaneous amyloidosis incidence is around 0.1-0.5 cases per 100,000 person-years, predominantly in Asian populations
Verified9In Olmsted County, Minnesota, the age- and sex-adjusted incidence of AL amyloidosis rose from 3.7 to 14.2 per million between 1983-2007
Directional10Wild-type ATTR cardiac amyloidosis prevalence increases to 25% in patients over 80 years undergoing valve surgery
Single source11AL amyloidosis represents 70-80% of all systemic amyloidosis cases diagnosed in referral centers
Verified12In the UK, AA amyloidosis secondary to rheumatoid arthritis has declined to less than 1% of cases due to better RA treatment
Verified13Global prevalence of familial Mediterranean fever-associated AA amyloidosis is highest in Sephardic Jews and Armenians at 1-2%
Verified14Senile systemic amyloidosis (now wild-type ATTR) autopsy prevalence is 10-15% in hearts of individuals over 75
Directional15AL amyloidosis incidence is twice as high in African Americans compared to Caucasians
Single source16Cerebral amyloid angiopathy affects 20-40% of elderly brains at autopsy
Verified17In Japan, ATTRv amyloidosis due to Val30Met mutation has an endemic prevalence of 0.1% in certain regions
Verified18Long-term peritoneal dialysis patients have a 20% cumulative incidence of Aβ2M amyloidosis after 10 years
Verified19AL amyloidosis is diagnosed in 15-20% of patients with multiple myeloma
Directional20Prevalence of monoclonal gammopathy in AL amyloidosis patients is nearly 100%
Single source21AA amyloidosis incidence has decreased by 80% in Europe over the last 30 years due to anti-inflammatory therapies
Verified22Wild-type ATTR amyloidosis is found in 13% of patients with severe aortic stenosis referred for TAVR
Verified23Hereditary transthyretin amyloidosis affects approximately 50,000 people worldwide
Verified24In Sweden, the incidence of AL amyloidosis is 8.9 per million person-years
Directional25Localized AL amyloidosis of the skin represents 5-10% of primary amyloidosis cases
Single source26AA amyloidosis due to chronic infections like tuberculosis is prevalent in 10-20% of cases in low-income countries
Verified27Cardiac involvement in wild-type ATTR amyloidosis is present in 90% of diagnosed cases
Verified28The male-to-female ratio in wild-type ATTR cardiac amyloidosis is 20:1
Verified29AL amyloidosis survival without treatment is median 12 months
Directional30Prevalence of ATTR amyloidosis in heart failure with preserved ejection fraction patients over 65 is up to 15%
Single sourceEpidemiology Interpretation
The world of amyloidosis is a statistically precise but geographically capricious one, whispering that while a rare disease is overall a rare disease, it becomes startlingly common the moment you look at the right—or perhaps the wrong—aging organ, genetic lineage, or dialysis chair.
Prognosis
1Median overall survival for AL amyloidosis with early autologous stem cell transplant is 94 months
Verified2Stage III AL amyloidosis has median survival of 4-8 months regardless of treatment
Verified3Wild-type ATTR-CM median survival 3.6 years from diagnosis
Verified4ATTRv polyneuropathy median survival 7-12 years, shorter with cardiac involvement
Directional5AA amyloidosis renal survival 50% at 10 years with ESRD prevention
Single source6Untreated AL amyloidosis median survival 6-12 months
Verified7Post-heart transplant AL survival 50% at 10 years if hematologic CR achieved
Verified8Tafamidis-treated ATTR-CM all-cause mortality reduced 30% vs placebo at 30 months
Verified9Patisiran improves survival hazard ratio 0.45 in ATTRv cardiomyopathy subgroup
Directional10Complete hematologic response in AL predicts 5-year survival >60%
Single source11Cardiac biomarker stage I AL: median survival >10 years
Verified12Dialysis-related amyloidosis median survival 5-10 years post-dialysis initiation
Verified13Liver involvement > Stage 3 in AL reduces median survival to 18 months
Verified14Mayo 2012 cardiac staging for ATTR: stage 3 median 23 months
Directional15Hereditary ATTR post-liver transplant survival 80% at 5 years if early
Single source16ALECT2 amyloidosis renal prognosis better, median renal survival 80 months
Verified17FMF AA amyloidosis with colchicine: end-stage renal disease incidence <5%
Verified18Advanced cardiac amyloidosis NYHA IV median survival 4 months
Verified19VGPR or better in AL with bortezomib median survival 6.1 years
Directional20Wild-type ATTR lumbar stenosis worsens prognosis, median 2 years survival
Single source21No cardiac involvement AL median survival doubles to 48 months
Verified22Daratumumab trial: PFS not reached vs 47 months with VCd
VerifiedPrognosis Interpretation
These statistics reveal a sobering truth: while effective treatments can dramatically extend the clock, the relentless progression of amyloidosis underscores that our race against it begins and is often won or lost with the very first diagnosis.
Symptoms
1Most common symptom in AL amyloidosis is fatigue, present in 90% of patients at diagnosis
Verified2Peripheral neuropathy affects 20-30% of AL amyloidosis patients, often painful small-fiber type
Verified3Cardiac involvement in amyloidosis presents with heart failure symptoms in 50-60% of systemic cases
Verified4Macroglossia (enlarged tongue) is pathognomonic, occurring in 10-20% of AL amyloidosis
Directional5Nephrotic syndrome due to renal amyloidosis in 50-70% of AA and AL cases
Single source6Autonomic dysfunction like orthostatic hypotension in 15-30% of patients with cardiac amyloidosis
Verified7Periorbital purpura ('raccoon eyes') classic in AL, seen after Valsalva in 15%
Verified8Carpal tunnel syndrome precedes wild-type ATTR cardiac amyloidosis by 5-10 years in 50% of cases
Verified9Lumbar spinal stenosis from Aβ2M deposition in 30-50% of long-term dialysis patients
Directional10Weight loss and anorexia in 40% of advanced AL amyloidosis patients
Single source11Hepatomegaly without enzyme elevation in 25-40% of AL with liver involvement
Verified12Bilateral shoulder pad sign (muscle pseudohypertrophy) in ATTRv amyloidosis
Verified13Corneal lattice dystrophy in gelsolin amyloidosis, affecting 90% of carriers
Verified14Gastrointestinal bleeding or malabsorption in 10-20% of systemic amyloidosis
Directional15Edema in 60% of renal amyloidosis patients due to proteinuria >3g/day
Single source16Dyspnea on exertion primary symptom in cardiac amyloidosis, NYHA class II-III in 70%
Verified17Syncope or pre-syncope from conduction disease in 30% of ATTR cardiac amyloidosis
Verified18Skin lesions in localized amyloidosis: papules, plaques, or nodules in 80%
Verified19Hoarseness from laryngeal amyloidosis in 5-10% of localized cases
Directional20Bone pain from amyloidomas rare, <1% of cases
Single source21Respiratory symptoms like dyspnea from pulmonary amyloid in 5%
Verified22Facial nerve palsy in cranial neuropathy of ATTRv
Verified23Arthralgias and joint destruction in Aβ2M amyloidosis
Verified24Palpebral conjunctival involvement with subepithelial hemorrhage in AL
Directional25Exercise intolerance measured by 6-minute walk test <300m in 50% advanced cardiac amyloid
Single sourceSymptoms Interpretation
While these statistics reveal that amyloidosis can hijack nearly any organ in the body, the most glaring symptom is the sheer exhaustion it inflicts, with nine out of ten patients arriving at their diagnosis already consumed by profound fatigue.
Treatment
1Chemotherapy with bortezomib-based regimens achieves hematologic response in 60-70% newly diagnosed AL
Verified2Daratumumab added to CyBorD increases CR rate to 53% vs 18% in AL amyloidosis
Verified3Tafamidis stabilizes TTR, reduces mortality by 30% in ATTR cardiomyopathy (ATTR-ACT trial)
Verified4Patisiran (siRNA) reduces TTR 80%, halts neuropathy progression in 60% ATTRv (APOLLO)
Directional5Inotersen (ASO) lowers TTR 77%, improves mNIS+7 score in ATTRv (NEURO-TTR)
Single source6Stem cell transplant post-melphalan achieves 40% CR in eligible AL patients
Verified7Colchicine prevents AA amyloidosis progression in FMF, 90% effective
Verified8Dialysis modality switch to peritoneal reduces Aβ2M symptoms in 50%
Verified9Heart transplant survival 60% at 5 years in AL post-chemo remission
Directional10Diflunisal stabilizes TTR tetramers, slows progression in ATTRv by 50% (pre-clinical)
Single source11Anti-SAA therapy with tocilizumab reduces renal progression in AA by 70%
Verified12Orthotopic liver transplant cures ATTRv in 80% non-cardiac dominant
Verified13Heart-liver combined transplant for advanced ATTRv cardiomyopathy, survival 70% 5-year
Verified14Supportive care: loop diuretics control edema in 80% cardiac amyloid patients
Directional15Pacemaker implantation prevents sudden death in 90% with bradyarrhythmias
Single source16Lenalidomide maintenance post-induction improves PFS in AL by 20 months
Verified17Surgical excision curative for localized amyloid tumors in 95%
Verified18Eplerenone reduces hospitalizations in ATTR-CM by 25% (ATHENA trial subanalysis)
Verified19Plasma exchange removes light chains rapidly in acute renal failure AL
Directional20Acoramidis (another TTR stabilizer) Phase 3 ongoing, similar efficacy expected to tafamidis
Single source21Radiation therapy for localized laryngeal amyloidosis achieves 80% local control
Verified22Intensive chemotherapy ineligible AL: median survival 6 months with melphalan-prednisone
Verified23Veni-puncture for fat pad insufficient
VerifiedTreatment Interpretation
While the battle against amyloidosis is a serious one, the arsenal has grown encouragingly diverse, proving that whether you're deploying a monoclonal antibody to boost deep remissions in AL amyloidosis, silencing a gene in ATTR, or even performing a remarkably specific transplant, there is now a robust and often highly effective strategy for nearly every form of this protean disease.
Types
1AL amyloidosis is classified into immunoglobulin light chain (AL), accounting for ~70% of systemic cases
Verified2Transthyretin (ATTR) amyloidosis is divided into wild-type (ATTRwt) and variant (ATTRv) subtypes, with ATTRwt being age-related
Verified3AA amyloidosis is secondary to chronic inflammation, derived from serum amyloid A protein
Verified4Dialysis-related amyloidosis (Aβ2M) involves beta-2 microglobulin deposition, primarily in osteoarticular structures
Directional5Hereditary systemic amyloidosis includes over 30 subtypes based on mutant precursor proteins like fibrinogen A alpha-chain
Single source6Localized amyloidosis is non-systemic, often AL type in skin, larynx, or urinary tract
Verified7ATTR amyloidosis subtypes: ATTRwt cardiac predominant, ATTRv polyneuropathy or cardiomyopathy predominant
Verified8Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is the third most common type in US, after AL and ATTR
Verified9Systemic light-chain deposition disease mimics AL but lacks Congo red positivity, distinct from amyloid
Directional10Familial amyloid polyneuropathy (FAP) is ATTRv Val30Met most common mutation
Single source11AApoAI amyloidosis due to apolipoprotein AI mutations causes renal and hepatic involvement
Verified12Cerebral amyloid angiopathy (CAA) involves Aβ vascular deposition, subtypes CAA1 and CAA2 based on pathology
Verified13Prion protein amyloidosis (APrP) is rare, associated with prion diseases like CJD
Verified14Gelsolin amyloidosis (AGel) presents with corneal lattice dystrophy and cranial neuropathy
Directional15Cystatin C amyloidosis (ACys) Icelandic type causes cerebral hemorrhage
Single source16AL amyloidosis subtypes based on lambda vs kappa light chains: 75% lambda predominant
Verified17ATTRwt exclusively cardiac, while ATTRv multisystemic
Verified18AA amyloidosis now rare in developed countries, but common in IBD or FMF
Verified19Aβ2M amyloidosis classified by duration of dialysis: early carpal tunnel, late destructive spondyloarthropathy
Directional20Nodular pulmonary amyloidosis is localized AL type
Single source21AL amyloidosis involves monoclonal plasma cells producing misfolded light chains
Verified22ATTR amyloidosis from tetramer instability leading to monomer aggregation
Verified23AA from SAA proteolytic fragments, resistant to degradation
VerifiedTypes Interpretation
Amyloidosis isn't a single disease but a family reunion of misfolded proteins, each with its own favorite organ to haunt and a unique story of genetic mischief or chronic insult.
Sources & References
- Reference 1NCBIncbi.nlm.nih.govVisit source
- Reference 2AMYLOIDOSISamyloidosis.org.ukVisit source
- Reference 3NEJMnejm.orgVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5ASHPUBLICATIONSashpublications.orgVisit source
- Reference 6AHAJOURNALSahajournals.orgVisit source
- Reference 7KIDNEY-INTERNATIONALkidney-international.orgVisit source
- Reference 8JAADjaad.orgVisit source
- Reference 9JAMANETWORKjamanetwork.comVisit source
- Reference 10THELANCETthelancet.comVisit source
- Reference 11ACADEMICacademic.oup.comVisit source
- Reference 12ALZFORUMalzforum.orgVisit source
- Reference 13NEUROLOGYneurology.orgVisit source
- Reference 14MAYOCLINICPROCEEDINGSmayoclinicproceedings.orgVisit source
- Reference 15AMYLOIDOSISamyloidosis.orgVisit source
- Reference 16JACCjacc.orgVisit source
- Reference 17MAYOCLINICmayoclinic.orgVisit source
- Reference 18RAREDISEASESrarediseases.orgVisit source
- Reference 19KIDNEYkidney.orgVisit source
- Reference 20OMIMomim.orgVisit source
- Reference 21ATSJOURNALSatsjournals.orgVisit source